|
1
|
Biermann JS, Adkins D, Benjamin R, et al:
Bone cancer. J Natl Compr Cancer Netw. 5:420–437. 2007.
|
|
2
|
Demetri GD, Baker LH, Benjamin RS, et al:
Soft tissue sarcoma. J Natl Compr Cancer Netw. 5:364–399.
2007.PubMed/NCBI
|
|
3
|
Marina N, Gebhardt M, Teot L and Gorlick
R: Biology and therapeutic advances for pediatric osteosarcoma.
Oncologist. 9:422–441. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Patel SR, Vadhan-Raj S, Burgess MA, et al:
Results of two consecutive trials of dose-intensive chemotherapy
with doxorubicin and ifosfamide in patients with sarcomas. Am J
Clin Oncol. 21:317–321. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zoncu R, Efeyan A and Sabatini DM: mTOR:
from growth signal integration to cancer, diabetes and ageing. Nat
Rev Mol Cell Biol. 12:21–35. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Guertin DA and Sabatini DM: An expanding
role for mTOR in cancer. Trends Mol Med. 11:353–361. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fasolo A and Sessa C: Targeting mTOR
pathways in human malignancies. Curr Pharm Des. 18:2766–2777. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Benjamin D, Colombi M, Moroni C and Hall
MN: Rapamycin passes the torch: a new generation of mTOR
inhibitors. Nat Rev Drug Discov. 10:868–880. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Houghton PJ: Everolimus. Clin Cancer Res.
16:1368–1372. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Guertin DA and Sabatini DM: The
pharmacology of mTOR inhibition. Sci Signal. 2:pe242009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Feldman ME, Apsel B, Uotila A, et al:
Active-site inhibitors of mTOR target rapamycin-resistant outputs
of mTORC1 and mTORC2. PLoS Biol. 7:e382009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yu K, Shi C, Toral-Barza L, et al: Beyond
rapalog therapy: preclinical pharmacology and antitumor activity of
WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and
mTORC2. Cancer Res. 70:621–631. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Thoreen CC, Kang SA, Chang JW, et al: An
ATP-competitive mammalian target of rapamycin inhibitor reveals
rapamycin-resistant functions of mTORC1. J Biol Chem.
284:8023–8032. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Janes MR, Limon JJ, So L, et al: Effective
and selective targeting of leukemia cells using a TORC1/2 kinase
inhibitor. Nat Med. 16:205–213. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Schenone S, Brullo C, Musumeci F, et al:
ATP-competitive inhibitors of mTOR: an update. Curr Med Chem.
18:2995–3014. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shao H, Gao C, Tang H, et al: Dual
targeting of mTORC1/C2 complexes enhances histone deacetylase
inhibitor-mediated anti-tumor efficacy in primary HCC cancer in
vitro and in vivo. J Hepatol. 56:176–183. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang YJ, Duan Y and Zheng XF: Targeting
the mTOR kinase domain: the second generation of mTOR inhibitors.
Drug Discov Today. 16:325–331. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bai X, Ma D, Liu A, et al: Rheb activates
mTOR by antagonizing its endogenous inhibitor, FKBP38. Science.
318:977–980. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li H, Lin J, Wang X, et al: Targeting of
mTORC2 prevents cell migration and promotes apoptosis in breast
cancer. Breast Cancer Res Treat. 134:1057–1066. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chou TC and Talalay P: Quantitative
analysis of dose-effect relationships: the combined effects of
multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li DM and Feng YM: Signaling mechanism of
cell adhesion molecules in breast cancer metastasis: potential
therapeutic targets. Breast Cancer Res Treat. 128:7–21. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Song G, Ouyang G and Bao S: The activation
of Akt/PKB signaling pathway and cell survival. J Cell Mol Med.
9:59–71. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cohen SM and Lippard SJ: Cisplatin: from
DNA damage to cancer chemotherapy. Prog Nucleic Acid Res Mol Biol.
67:93–130. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Thoreen CC and Sabatini DM: Rapamycin
inhibits mTORC1, but not completely. Autophagy. 5:725–726. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Carew JS, Kelly KR and Nawrocki ST:
Mechanisms of mTOR inhibitor resistance in cancer therapy. Target
Oncol. 6:17–27. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Masri J, Bernath A, Martin J, et al:
mTORC2 activity is elevated in gliomas and promotes growth and cell
motility via overexpression of rictor. Cancer Res. 67:11712–11720.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Guertin DA, Stevens DM, Saitoh M, et al:
mTOR complex 2 is required for the development of prostate cancer
induced by Pten loss in mice. Cancer Cell. 15:148–159. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shorning BY, Griffiths D and Clarke AR:
Lkb1 and Pten synergise to suppress mTOR-mediated tumorigenesis and
epithelial-mesenchymal transition in the mouse bladder. PLoS One.
6:e162092011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gulhati P, Bowen KA, Liu J, et al: mTORC1
and mTORC2 regulate EMT, motility, and metastasis of colorectal
cancer via RhoA and Rac1 signaling pathways. Cancer Res.
71:3246–3256. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Inoki K, Mori H, Wang J, et al: mTORC1
activation in podocytes is a critical step in the development of
diabetic nephropathy in mice. J Clin Invest. 121:2181–2196. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Proud CG: mTOR signalling in health and
disease. Biochem Soc Trans. 39:431–436. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sparks CA and Guertin DA: Targeting mTOR:
prospects for mTOR complex 2 inhibitors in cancer therapy.
Oncogene. 29:3733–3744. 2010. View Article : Google Scholar : PubMed/NCBI
|
